|
GEO identifiers and data sets used for pathway activation method comparison |
||
| GEO ID |
Subgroup 1 (Baseline) |
Subgroup 2 |
|
|
||
| GDS1062 |
Metastasis-negative squamous cell carcinoma (8) |
Metastasis-positive squamous cell carcinoma (14) |
| GDS1067 |
Monoclonal gammopathy (7) |
Multiple myeloma (39) |
| GDS1210 |
Normal gastric tissue (8) |
Gastric carcinoma (14) |
| GDS1220 |
Normal pleural tissue (8) |
Malignant mesothelioma (40) |
| GDS1221 |
Peripheral blood, CML responsive Gleevec (9) |
Peripheral blood, CML not responsive Gleevec (7) |
| GDS1231 |
Enriched for hematopoietic stem cells (9) |
Enriched for committed hematopoietic cells (9) |
| GDS1329 |
'Basal' breast tumors (16) |
'Luminal' breast tumors (27) |
| GDS1329 |
'Basal' breast tumors (16) |
'Apocrine' breast tumors (6) |
| GDS1332 |
Whole blood normal controls (14) |
Whole blood symptomatic Huntington disease (12) |
|
The numbers in parentheses are the number of samples in each subgroup. CML, chronic myelogenous leukemia. References are provided in the main text. | ||
Levine et al. Genome Biology 2006 7:R93 doi:10.1186/gb-2006-7-10-r93 |
||